Duchenne Community Faces Crisis as Second Death Linked to Gene Therapy
TL;DR Summary
The Duchenne muscular dystrophy community is distressed after the death of a second teenager from liver failure linked to Sarepta's gene therapy, Elevidys, raising concerns and division over the therapy's safety and hope for treatment.
Topics:business#duchenne-muscular-dystrophy#elevidys#gene-therapy#health#liver-failure#sarepta-therapeutics
- After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry statnews.com
- Second patient death reported with gene therapy for muscular dystrophy AP News
- Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures WSJ
- Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug Investopedia
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Business Wire
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
86%
257 → 35 words
Want the full story? Read the original article
Read on statnews.com